Silveray is a deep‑tech spin‑out that develops flexible, low‑cost, colour-capable X‑ray detectors based on a patented nanoparticle semiconductor ink (NPX), initially commercialising a Digital X‑ray Film (DXF) for industrial non‑destructive testing with plans to expand into medical imaging[1][6].
High‑Level Overview
- Silveray builds flexible, large‑area direct‑conversion X‑ray detectors using a nanoparticle‑doped semiconductor ink called NPX that can be coated onto flexible backplanes to produce reusable, curved or flat detector films (branded DXF) that digitise radiographic workflows[1][6].
- The product serves industrial NDT (weld and pipe inspection, corrosion detection) today and targets medical diagnostics (e.g., mammography and other applications) over time[4][1].
- The company’s value proposition is lower dose sensitivity, spectral (colour) X‑ray capability, flexibility to conform to complex geometries, faster digital workflows versus analogue film, and cost advantages that enable broader access to X‑ray imaging[1][6][4].
- Growth momentum: Silveray is a University of Surrey spin‑out (founded 2018), relocated to Greater Manchester, has won recognition such as the Institute of Physics Business Start‑Up Award, and completed a €4.2M seed extension led by Northern Gritstone with participation from strategic investors and specialist funds to prepare an industrial launch planned for 2025[3][1][4].
Origin Story
- Founding and research roots: Silveray emerged as a University of Surrey/Advanced Technology Institute spin‑out based on pioneering research into nanoparticle X‑ray absorption and semiconductor inks led by Professor Ravi Silva and colleagues; the company was founded in 2018 to commercialise that work[3][1].
- How the idea emerged: Academic work on incorporating high‑Z elements into semiconductor polymers produced a solution‑processable NPX ink that directly converts X‑rays to charge while retaining spectral information, enabling the concept of *colour* X‑rays on a flexible substrate[1][3].
- Early traction / pivotal moments: Key milestones include patenting NPX, winning the IOP Business Start‑Up Award, raising a seed extension round (€4.2M) with Northern Gritstone and others, strategic collaboration with X‑ray specialists and industrial lead customers for NDT, and moving toward an industrial product launch and revenue generation in 2025[1][4][3].
Core Differentiators
- Proprietary material (NPX): A nanoparticle‑doped direct‑conversion semiconductor ink that is solution‑processable, sensitive at low dose, and preserves spectral information enabling colour X‑ray imaging[1][6].
- Flexibility and form factor: Can be coated onto flexible plastics and curved surfaces, allowing detectors to wrap around pipes or conform to anatomy—opening use cases that rigid flat panels cannot[4][6].
- Cost and workflow fit: Designed as a semi‑disposable Digital X‑ray Film to replace analogue radiographic film—offering instant digital images, reduced handling/processing time, and potential operational savings for industrial users[6][4].
- Market entry strategy: Targeting industrial NDT first (lower regulatory barriers) to commercialise and validate product with lead customers before entering healthcare where regulatory requirements are higher[1].
- Recognition and backing: Academic pedigree (Surrey ATI), industry awards, and strategic investors (Northern Gritstone, Hamamatsu Ventures, ACF Investors, others) that bring capital and domain expertise[3][4][2].
Role in the Broader Tech Landscape
- Trend alignment: Rides the convergence of advanced materials, flexible electronics, and digital imaging—part of a broader push to modernise legacy inspection and medical imaging workflows with cheaper, more versatile sensors[1][6].
- Timing matters because many industries still rely on analogue film or rigid panels; offering a flexible, lower‑cost digital alternative addresses clear inefficiencies in inspection throughput and access to diagnostics in lower‑resource settings[4][1].
- Market forces in their favor include rising demand for digitisation in industrial inspection, increasing focus on early and more accurate diagnostics in healthcare, and strategic interest from imaging incumbents seeking sensor innovation[4][1].
- Ecosystem influence: By lowering cost and improving form factors, Silveray could broaden where and how X‑ray imaging is used (e.g., confined spaces in NDT, more accessible medical imaging in regional hospitals), and stimulate new use cases and third‑party software/AI for spectral X‑ray analysis[1][4].
Quick Take & Future Outlook
- Near term: Commercial roll‑out in industrial NDT is the immediate priority (industrial DXF launch targeted for 2025), which should validate manufacturing, reliability and customer economics while generating early revenue[4][6].
- Medium term: Regulatory clearance and clinical validation would enable moves into medical imaging (mammography and other modalities) where the spectral/colour capability and conformable detectors could differentiate clinical workflows and patient comfort[1][3].
- Risks and enablers: Key dependencies include scaling production of NPX‑coated detector films at cost, proving long‑term durability and image quality in field conditions, and navigating medical regulatory pathways for clinical use[6][4]. Strategic partnerships (e.g., with sensor/readout providers and clinical institutions) and investors with domain expertise (e.g., Hamamatsu Ventures) materially de‑risk these steps[4][2].
- If Silveray successfully executes, it could meaningfully disrupt analogue radiography in industry, accelerate digitisation, and open new clinical imaging formats—bringing the opening claim (colour, flexible X‑ray detectors) from lab to widespread use[1][4].
Key sources for this profile: Institute of Physics award page and Silveray technology descriptions (NPX, DXF)[1][6]; University of Surrey press release on the spin‑out and award[3]; news on financing and commercial plans (EU‑Startups coverage of the €4.2M raise)[4]; investor portfolio listing (ACF Investors)[2].
